News Releases Year None202120202019201820172016 BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i) 09.15.2021 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 09.08.2021 BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors 08.25.2021 BridgeBio Pharma, Inc. Appoints Finance and Pharmaceutical Leaders Fred Hassan, Andrea Ellis and Douglas Dachille to its Board of Directors 08.18.2021 BridgeBio Pharma, Inc. Reports Second Quarter 2021 Financial Results and Business Update 08.05.2021 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 08.04.2021 BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations 07.27.2021 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 07.12.2021 BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions 07.08.2021 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 06.14.2021 BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1 06.01.2021 BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma 05.28.2021 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 05.14.2021 BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia 05.14.2021 BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update 05.06.2021 BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions 04.13.2021 BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases 04.13.2021 BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers 04.13.2021 BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases 04.13.2021 BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers 04.13.2021 BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research 04.13.2021 BridgeBio Pharma and Brown University Announce Partnership to Drive the Advancement of Academic Innovations in Genetically Driven Diseases into Potential Therapeutics for Patients 04.13.2021 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 04.06.2021 BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology 03.31.2021 BridgeBio Pharma Announces Proof-of-Concept Data of Encaleret in ADH1 at the Endocrine Society’s 2021 Annual Meeting 03.20.2021 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 03.02.2021 BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A 02.28.2021 BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update 02.25.2021 BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting 02.24.2021 BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i) 02.19.2021 BridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of Common Stock 02.12.2021 BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock 02.11.2021 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 02.05.2021 BridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations 02.02.2021 BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc. 01.26.2021 BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes 01.25.2021 BridgeBio Pharma, Inc. Announces Proposed Offering of $400 Million Convertible Senior Notes 01.25.2021 Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc. 01.19.2021 BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger 01.13.2021 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 01.06.2021 Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote “FOR” Proposed Merger 01.04.2021
